General
Preferred name
RIDAFOROLIMUS
Synonyms
MK-8669, AP-23573, Ridaforolimus ()
Deforolimus ()
MK-8669 ()
AP23573 ()
Deforolimus (Ridaforolimus) ()
Ridaforolimus (Deforolimus, MK-8669) ()
AP 23573 ()
AP-23573 ()
MK-8669 ()
P&D ID
PD046430
CAS
572924-54-0
Tags
natural product
drug
available
Drug indication
Sarcoma
Drug Status
investigational
approved
Max Phase
Phase 3
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Ridaforolimus is an investigational targeted and small-molecule inhibitor of the protein kinase mTOR . mTOR inhibition is hypothesised to provide maintenance therapy for patients with metastatic soft-tissue and bone sarcoma who generally have a poor prognosis despite receiving chemotherapy . (GtoPdb)
Compound Sets
17
AdooQ Bioactive Compound Library
A10295
Cayman Chemical Bioactives
10543
ChEMBL Drugs
CHEMBL2103839
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
7884
Concise Guide to Pharmacology 2019/20
7884
Concise Guide to Pharmacology 2021/22
7884
Concise Guide to Pharmacology 2023/24
7884
Drug Repurposing Hub
DrugBank
DB06233
DrugCentral
4778
DrugCentral Approved Drugs
4778
DrugMAP
DMLHEU7
Guide to Pharmacology
7884
MedChem Express Bioactive Compound Library
HY-50908
Selleckchem Bioactive Compound Library
Deforolimus
TargetMol Bioactive Compound Library
T6334
External IDs
25
Properties
(calculated by RDKit )
Molecular Weight
989.56
Hydrogen Bond Acceptors
14
Hydrogen Bond Donors
2
Rotatable Bonds
8
Ring Count
4
Aromatic Ring Count
0
cLogP
7.74
TPSA
201.5
Fraction CSP3
0.75
Chiral centers
15.0
Largest ring
29.0
QED
0.1
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Targets
MTOR
Pathway
PI3K/Akt/mTOR signaling
Anti-infection
Autophagy
PI3K/Akt/mTOR
MOA
mTOR
mTOR inhibitor
Target
Bacterial
FKBP,mTOR
Source data